Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker

Phase 2

Completed

• Conditions: Heart Failure
• Interventions: Drug: Placebo (treatment 1); Drug: BAY1067197 (treatment 2)

• Registration Number: NCT01945606
• Lead Sponsor: Bayer

Brief Summary

This is a study to investigate the safety and tolerability of the partial A1 agonist BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied as a single dose of 30 mg in addition to standard therapy including a beta-blocker. The aim of the study is to assess if a single oral dose of 30 mg BAY1067197 is well tolerated when given on top of standard therapy for heart failure, particularly ß-blocker treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-09-16
• Study First Submitted QC: 2013-09-16
• Study First Posted: 2013-09-18
• Study Start: 2013-11-29
• Primary Completion: 2014-09-09
• Study Completion: 2015-03-17
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-17
• Last Update Posted: 2019-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Stable systolic heart failure (heart failure with reduced ejection fraction, heart failure with reduced ejection fraction [HFrEF]; New York Heart Association [NYHA] I-III) in sinus rhythm with a documented ejection fraction (EF) ≤45% within the last 3 months
• Stable standard heart failure (HF) therapy including intermediate to high dose β-blocker with either ≥ 95 mg metoprolol succinate (controlled release tablet), ≥ 5mg Bisoprolol (immediate release [IR] -tablet) or ≥5mg Nebivolol (IR tablet) for at least 4 weeks. Additional intake of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers and optional aldosterone-receptor antagonists, diuretics or digitalis is allowed
• Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate and a history of vasomotor symptoms) or women without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy (documented by medical report verification). Men enrolled in this study must agree to use adequate barrier birth control measures during the treatment period of the study and for 12 weeks after receiving the investigational medicinal product (IMP)
• Male patients must agree not to act as sperm donor for 12 weeks after dosing
• Ethnicity: White
• Body mass index (BMI): above/equal 18.0 and below/equal 29.9 kg/m²
• Age: 18 to 75 years (inclusive) at the first screening visit

Read More

Exclusion Criteria

• Biventricular pacing/active cardiac resynchronization therapy (CRT) device
• Dependency on pacemaker or implantable cardioverter-defibrillator (ICD) device with pacemaker dependency (a paced ventricular rhythm > 5% of heart activity)
• A history of relevant diseases of vital organs other than the heart, of the central nervous system or other organs
• Known hypersensitivity to the study preparations (active substances or excipients of the preparations) or to any other β-blocker
• Current or history of AV-Block > I°
• Unstable condition, indicated by requirement of IV drug (diuretic, inotrope, etc.) or NYHA IV
• Acute Coronary Syndrome (defined as unstable angina [UA], non-ST elevation myocardial infarction [NSTEMI], ST elevation myocardial infarction [STEMI]) within 3 months prior to first study drug administration
• History of asthma or chronic obstructive pulmonary disease (COPD) ≥ global initiative for chronic obstructive lung disease (GOLD) II and/or allergic asthma
• Women of childbearing potential, pregnancy or breastfeeding

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo and BAY1067197	BAY1067197 (treatment 2)	Patients will get both treatment 1 and 2
Placebo and BAY1067197	Placebo (treatment 1)	Patients will get both treatment 1 and 2

Primary Outcome Measures

Name	Time	Method
Number of patients with occurrence of AV-Block > I°	up to 48 hours

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic profile determined by tmax	up to 24 hours
Heart rate	multiple time points up to 24 hours
Pharmacokinetic profile determined by t1/2	up to 22 days
Blood pressure	multiple time points up to 24 hours
Number of participants with adverse events as a measure of safety and tolerability	up to 48 hours